Among the many cardiovascular and lung diseases that threaten human health, pulmonary heart disease, with its unique morbidity mechanisms and more complex clinical manifestations, has become one of the major causes in the medical field. Pulmonary heart disease, referred to as chronic pulmonary heart disease, is caused by chronic changes in the pulmonary tissue, pulmonary arteries or thorax that cause the pulmonary structure and function, resulting in increased pulmonary vascular resistance, increased pulmonary arterial pressure, expansion of the right heart, fatness, or a heart disease with or without right heart failure.
Pulmonary heart diseases are mostly caused by chronic diseases in the lungs. The most common of these is chronic bronchitis combined obstructive pneumoconiosis. Long-term chronic bronchitis, which repeatedly stimulates bronchial mucous membranes, leads to thicker bronchial walls, a narrow cavity, and obstructs the flow of gas to and from the lungs, leading to excessive pneumatic inflating, swelling and emphysema. As conditions develop, the destruction of the pulmonary vascular bed, increased lung cycling resistance and increased pressure on the pulmonary artery, for example, some long-smoking patients, harmful substances in tobacco continue to damage respiratory and lung tissue, and are highly likely to lead to chronic bronchitis, which tends to develop into emphysema without effective control until it causes pulmonary heart disease.
In addition to chronic obstructive pulmonary disease, bronchial pathologies can also be cause of pulmonary heart disease, such as bronchial asthma, bronchial extension, etc. Pneumococular constrictions, remodelling and increasing lung retrenchment can cause pulmonary aerobic disorders in patients with bronchial asthma due to chronic inflammation and convulsions in the airway. Pneumonic expansion caused by the destruction and deformation of the bronchial walls not only affects the exchange of gases, but is also prone to repeated lung infections, exacerbating pathology changes in the lungs and contributing to the development of pulmonary heart disease. Also closely related to pulmonary heart disease are chest malformations, pulmonary vascular diseases, etc. The normal expansion of the lung is limited by the pectrophagus, inhibiting the aerobic activity of the lung, and pulmonary arterial pressure and pulmonary anemic embolism directly contribute to the increase in pulmonary artery pressure and increase the right-heart load, leading to pulmonary heart disease.
The clinical performance of pulmonary heart patients is very typical and of a phased nature, with the main symptoms occurring during the pulmonary and heart function recovery period being chronic coughing, coughing, short-temperature and increased after-activity. These symptoms are often caused by underlying pulmonary diseases, but as the condition progresses, the pulmonary artery pressure gradually develops and the patient begins to show signs of weakness and reduced labour resilience. During the medical examination, pulmonary osmosis signs such as barrel chests, wide rib gaps and cropping are present, accompanied by a pulmonary arteryal pedal larvae in the second diarrhea, indicating an increase in lung artery pressure. Some patients may also experience an increase in the right-heart load, such as cardiac artery.
When the illness progresses to the age of non-reparation, there is a marked increase in the patient ‘ s symptoms, and he/she suffers from increased respiratory difficulties, even when he/she is resting, and he/she suffers from respiratory failure in the form of hypoxiaemia, hypercarbonate, etc. There is also an increase in reductive haemoglobins in the blood, with the possibility that the skin mucous membranes of the patient may appear. At the same time, symptoms of right-heart failure occur, such as edema, abdominal water, liver and constriction. Eedema generally begins with lower limbs and spreads upwards, with all-body oedema when severe, hepatic swelling as a result of silt and long-term silt may lead to damage to his liver function. In addition, patients suffer from heart disorders that seriously endanger their lives and health.
How to diagnose pulmonary heart disease? A comprehensive diagnosis is needed. First, detailed medical history inquiries are essential, and doctors will know whether the patient has a history of chronic lung disease, chest profile disease, etc. The medical examination focused on lung and heart signs, such as pulmonary emphysema, cardiac noises, cardiac profuse, etc. mentioned above. In terms of laboratory examinations, the respiratory function of patients can be assessed through an arterial blood and gas analysis to determine whether they have low aerobics, high carbonate and acid alkali balance disorders. Regular blood tests reveal the presence of infection in patients, as lung infections are often the cause of acute increases in pulmonary heart disease and may increase in white cell count and the proportion of neutral particles at the time of infection. A chest X-line examination shows chronic lung pathologies, such as the visual characteristics of pneumoconiosis, and can also observe cardiac changes such as prominent pulmonary arteries and right-heart increases. An electrocardiogram shows the right side of the axle, the pulmonary P-waves, and suggests the right room is fat, the heart disorder, etc. An ultrasound cardiac chart allows for the accurate measurement of the size and thickness of the right heart chamber, thus assessing the pulmonary artery pressure and the condensation function of the heart.
For the treatment of pulmonary heart disease, control of infection, improvement of respiratory function, correction of oxygen deficiency and carbon dioxide retention, control of respiratory failure and heart failure, and prevention of complications are most critical. The acute increase in pulmonary heart disease is usually due to lung infections, so that the control of infection is a key component. Doctors will select sensitive antibacterials for treatment based on sapling and drug-sensitive tests. In terms of improved respiratory function, a variety of drugs can be used, such as aerobics, bronchial extremizers and slurry. Oxygen helps to saturate the patient ‘ s haematological saturation and to reduce the aerobic deficiency symptoms; bronchic expansions, such as salbutamol and aminoline, can ease the bronchial smoothing muscles, which improves the ventilation; and gills, such as ammonia bromine, can be very helpful in diluting the slurry, prompting it to discharge from the body. In case of respiratory failure, there may be a need for zero-iron pressure or mechanical ventilation to maintain effective respiratory support.
With regard to the control of heart failure, care must be taken to use urinants, starting with small doses. Diuretants such as hydroxychloride, propene, etc. can reduce oedema and heart loads, but overuse can lead to electrolyte disorders, mucous glucosis and impotence. The strength of acoustics such as geosin enhances myocardial constriction, but pulmonary heart patients are less resistant to the strong and are vulnerable to oceanic yellow poisoning due to oxygen deficiency, electrolytic disorders, etc. Hemopharmaceutical concentrations and EKG changes are also closely monitored. Pulmonary artery stress can be mitigated by phenolamine, but it needs to be used with caution, depending on the patient ‘ s physical condition.
The prognosis of pulmonary heart patients is closely related to factors such as the severity of the condition, the availability of timely and effective treatment and patient dependence. Pneumococcal disease prevention and development are essential. Actively treating pre-emergence diseases, such as chronic pulmonary diseases, cessation of alcohol and tobacco, enhancement of physical activity, physical improvement, and prevention of respiratory infections. Influenza and pneumonia vaccinations during the flu season can also reduce the risk of infection. At the same time, regular medical check-ups are conducted, early detection and intervention of pulmonary and pulmonary risk factors and monitoring of pulmonary and pulmonary functions.
As a co-infection, pulmonary heart disease reduces the quality of life of patients, while at the same time there are serious life and health hazards. Through in-depth knowledge of their causes, clinical performance, diagnostic methods and treatment strategies, and enhanced preventive measures, patients can be helped to better respond to this health challenge and to improve their prognosis in order to win the fight against disease.
